Stoke Therapeutics (STOK) Stock Forecast & Price Target

Compare

440 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

STOK Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Stoke

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

STOK Stock 12 Month Forecast

Average Price Target

$23.93

▲(39.37% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $23.93 with a high forecast of $35.00 and a low forecast of $18.00. The average price target represents a 39.37% change from the last price of $17.17.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","36":"$36","12.75":"$12.75","20.5":"$20.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.75,20.5,28.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.91,14.60923076923077,16.30846153846154,18.00769230769231,19.706923076923076,21.40615384615385,23.105384615384615,24.804615384615385,26.503846153846155,28.203076923076924,29.902307692307694,31.601538461538464,33.300769230769234,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.91,13.757692307692308,14.605384615384615,15.453076923076923,16.30076923076923,17.14846153846154,17.996153846153845,18.843846153846155,19.69153846153846,20.53923076923077,21.386923076923075,22.234615384615385,23.082307692307694,{"y":23.93,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.91,13.301538461538462,13.693076923076923,14.084615384615384,14.476153846153846,14.867692307692307,15.259230769230768,15.650769230769232,16.04230769230769,16.433846153846154,16.825384615384614,17.216923076923077,17.60846153846154,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$23.93

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dex Genotek

TR | OpenAI - 4o

$19→$18.5

Hold

7.75%

Upside

Downgraded

08/15/25

AI Generated ArticleAI Generated Article

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

08/13/25

Stoke Therapeutics: Promising Outlook with Strong Financial Position and Advancing Clinical Trials Justifies Buy Rating

Joseph Stringer

Needham

$22

Buy

28.13%

Upside

Reiterated

08/13/25

Positive Outlook for Stoke Therapeutics: Promising Clinical Data and Strong Financial Position

Marc Goodman

Leerink Partners

$18

Buy

4.83%

Upside

Reiterated

08/13/25

Stoke Therapeutics (STOK) Receives a Buy from Leerink PartnersYear 3 OLE data on Zorevunersen’s efficacy continue to impress, and we remain Outperform.

Ananda Ghosh

H.C. Wainwright

$35

Buy

103.84%

Upside

Reiterated

08/13/25

Promising Developments in Stoke Therapeutics' Clinical Trials Support Buy Rating

Rudy Li

Chardan Capital

$24

Buy

39.78%

Upside

Reiterated

08/13/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Lyra Therapeutics (NASDAQ: LYRA), Stoke Therapeutics (NASDAQ: STOK) and Astria Therapeutics (NASDAQ: ATXS)

Andrew Tsai

Jefferies

$30

Buy

74.72%

Upside

Initiated

07/18/25

Stoke Therapeutics initiated with a Buy at JefferiesStoke Therapeutics initiated with a Buy at Jefferies

Sumant Kulkarni

Canaccord Genuity

$20

Buy

16.48%

Upside

Reiterated

07/10/25

Canaccord Genuity Keeps Their Buy Rating on Stoke Therapeutics (STOK)

Thomas Shrader

BTIG

$29

Buy

68.90%

Upside

Reiterated

05/13/25

Stoke Therapeutics' Promising Outlook: Buy Rating Backed by Zorevenersen's Potential and Strong Financial Position

Unknown Analyst

Cantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

01/08/25

Cantor Fitzgerald reiterates Overweight Rating on Stoke Therapeutics (STOK)Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Stoke Therapeutics (NASDAQ: STOK).

Jessica Fye

J.P. Morgan

$15

Hold

-12.64%

Downside

Reiterated

11/06/24

Analysts Conflicted on These Healthcare Names: AnaptysBio (NASDAQ: ANAB), Stoke Therapeutics (NASDAQ: STOK) and Immatics (NASDAQ: IMTX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dex Genotek

TR | OpenAI - 4o

$19→$18.5

Hold

7.75%

Upside

Downgraded

08/15/25

AI Generated ArticleAI Generated Article

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

08/13/25

Stoke Therapeutics: Promising Outlook with Strong Financial Position and Advancing Clinical Trials Justifies Buy Rating

Joseph Stringer

Needham

$22

Buy

28.13%

Upside

Reiterated

08/13/25

Positive Outlook for Stoke Therapeutics: Promising Clinical Data and Strong Financial Position

Marc Goodman

Leerink Partners

$18

Buy

4.83%

Upside

Reiterated

08/13/25

Stoke Therapeutics (STOK) Receives a Buy from Leerink PartnersYear 3 OLE data on Zorevunersen’s efficacy continue to impress, and we remain Outperform.

Ananda Ghosh

H.C. Wainwright

$35

Buy

103.84%

Upside

Reiterated

08/13/25

Promising Developments in Stoke Therapeutics' Clinical Trials Support Buy Rating

Rudy Li

Chardan Capital

$24

Buy

39.78%

Upside

Reiterated

08/13/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Lyra Therapeutics (NASDAQ: LYRA), Stoke Therapeutics (NASDAQ: STOK) and Astria Therapeutics (NASDAQ: ATXS)

Andrew Tsai

Jefferies

$30

Buy

74.72%

Upside

Initiated

07/18/25

Stoke Therapeutics initiated with a Buy at JefferiesStoke Therapeutics initiated with a Buy at Jefferies

Sumant Kulkarni

Canaccord Genuity

$20

Buy

16.48%

Upside

Reiterated

07/10/25

Canaccord Genuity Keeps Their Buy Rating on Stoke Therapeutics (STOK)

Thomas Shrader

BTIG

$29

Buy

68.90%

Upside

Reiterated

05/13/25

Stoke Therapeutics' Promising Outlook: Buy Rating Backed by Zorevenersen's Potential and Strong Financial Position

Unknown Analyst

Cantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

01/08/25

Cantor Fitzgerald reiterates Overweight Rating on Stoke Therapeutics (STOK)Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Stoke Therapeutics (NASDAQ: STOK).

Jessica Fye

J.P. Morgan

$15

Hold

-12.64%

Downside

Reiterated

11/06/24

Analysts Conflicted on These Healthcare Names: AnaptysBio (NASDAQ: ANAB), Stoke Therapeutics (NASDAQ: STOK) and Immatics (NASDAQ: IMTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Stoke Therapeutics

1 Month

xxx

Success Rate

19/35 ratings generated profit

Average Return

+0.15%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.29% of your transactions generating a profit, with an average return of +0.15% per trade.

3 Months

xxx

Success Rate

8/14 ratings generated profit

Average Return

+3.63%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +3.63% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

9/14 ratings generated profit

Average Return

+33.86%

reiterated a buy rating 3 days ago

Copying Yaron Werber's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +33.86% per trade.

2 Years

xxx

Success Rate

13/14 ratings generated profit

Average Return

+39.33%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +39.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

STOK Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, STOK has received 15 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. STOK average Analyst price target in the past 3 months is 23.93.

Each month's total comprises the sum of three months' worth of ratings.

STOK Financial Forecast

STOK Earnings Forecast

Next quarter’s earnings estimate for STOK is -$0.58 with a range of -$0.81 to -$0.39. The previous quarter’s EPS was -$0.40. STOK beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.26% of the time in the same period. In the last calendar year STOK has Outperformed its overall industry.

STOK Sales Forecast

Next quarter’s sales forecast for STOK is $6.06M with a range of $3.00M to $12.00M. The previous quarter’s sales results were $13.82M. STOK beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.42% of the time in the same period. In the last calendar year STOK has Outperformed its overall industry.

STOK Stock Forecast FAQ

What is STOK’s average 12-month price target, according to analysts?

Based on analyst ratings, Stoke Therapeutics Inc’s 12-month average price target is 23.93.

What is STOK’s upside potential, based on the analysts’ average price target?

Stoke Therapeutics Inc has 39.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is STOK a Buy, Sell or Hold?

Stoke Therapeutics Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Stoke Therapeutics Inc’s price target?

The average price target for Stoke Therapeutics Inc is 23.93. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $18.00. The average price target represents 39.37% Increase from the current price of $17.17.

What do analysts say about Stoke Therapeutics Inc?

Stoke Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of STOK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Stoke Therapeutics (STOK) Stock Forecast & Price Target

STOK Analyst Ratings

STOK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Stoke Therapeutics

STOK Analyst Recommendation Trends

STOK Financial Forecast

STOK Earnings Forecast

STOK Sales Forecast

STOK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts